Welling Jorrit B A, Koster T David, Slebos Dirk-Jan
Department of Pulmonary Diseases, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Groningen Research Institute for Asthma and COPD, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Expert Rev Med Devices. 2023 Jul-Dec;20(9):721-727. doi: 10.1080/17434440.2023.2233435. Epub 2023 Jul 7.
One-way endobronchial valve treatment improves lung function, exercise capacity, and quality of live in patients with severe emphysema and hyperinflation. Other areas of therapeutic application include treatment of persistent air leak (PAL), giant emphysematous bullae, native lung hyperinflation, hemoptysis, and tuberculosis.
In this review, we will assess the clinical evidence and safety of the different applications of one-way endobronchial valves (EBV).
There is solid clinical evidence for the use of one-way EBV for lung volume reduction in emphysema. Treatment with one-way EBV can be considered for the treatment of PAL. The application of one-way EBV for giant bullae, post lung transplant native lung hyperinflation, hemoptysis, and tuberculosis is under investigation and more research is required to investigate the efficacy and safety of these applications.
单向支气管内瓣膜治疗可改善重度肺气肿和肺过度充气患者的肺功能、运动能力及生活质量。治疗应用的其他领域包括持续性气胸（PAL）、巨大肺气肿性肺大疱、健侧肺过度充气、咯血和肺结核。
在本综述中，我们将评估单向支气管内瓣膜（EBV）不同应用的临床证据和安全性。
有确凿的临床证据支持使用单向EBV进行肺气肿的肺减容治疗。可考虑使用单向EBV治疗PAL。单向EBV在巨大肺大疱、肺移植后健侧肺过度充气、咯血和肺结核方面的应用正在研究中，需要更多研究来调查这些应用的疗效和安全性。
